Cargando…

Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia

BACKGROUND: Patients with psychosis frequently use a variety of psychotropic medicines, many of which have anticholinergic effects that can impair cognition. Therefore, this study aimed to evaluate whether there is an association between medications used for neuropsychological disorders/symptoms and...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Chadia, Salameh, Pascale, Sacre, Hala, Clément, Jean-Pierre, Calvet, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872384/
https://www.ncbi.nlm.nih.gov/pubmed/36694187
http://dx.doi.org/10.1186/s12888-023-04552-y
_version_ 1784877391952216064
author Haddad, Chadia
Salameh, Pascale
Sacre, Hala
Clément, Jean-Pierre
Calvet, Benjamin
author_facet Haddad, Chadia
Salameh, Pascale
Sacre, Hala
Clément, Jean-Pierre
Calvet, Benjamin
author_sort Haddad, Chadia
collection PubMed
description BACKGROUND: Patients with psychosis frequently use a variety of psychotropic medicines, many of which have anticholinergic effects that can impair cognition. Therefore, this study aimed to evaluate whether there is an association between medications used for neuropsychological disorders/symptoms and cognition in patients with schizophrenia, focusing on their anticholinergic load and antipsychotic doses. STUDY DESIGN: A cross-sectional study between July 2019 and Mars 2020 at the Psychiatric Hospital of the Cross-Lebanon enrolled 120 inpatients diagnosed with schizophrenia. The total anticholinergic burden was calculated based on the Anticholinergic Drug Scale (ADS), and the chlorpromazine equivalent dose was calculated using the Andreasen method to assess the relative antipsychotic dose. Also, the objective cognition was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS) tool. Study results. A significantly higher BACS total score (r = -0.33, p < 0.001), higher verbal memory (r = -0.26, p = 0.004), higher working memory (r = -0.20, p = 0.03), higher motor speed (r = -0.36, p < 0.001), and higher attention and speed of information processing (r = -0.27, p = 0.003) were significantly associated with lower chlorpromazine equivalent dose. Higher ADS (Standardized Beta (SB) = -.22; p = .028), higher chlorpromazine equivalent dose (SB = -.30; p = .001), and taking mood stabilizer medications (SB = -.24; p = .004) were significantly associated with lower cognition. CONCLUSION: This study confirms that the cognitive functions of chronic patients with schizophrenia may be affected by medications and their anticholinergic burden. More studies are needed to explain the role of cholinergic neurotransmission and general neurochemical mechanisms in the cognitive impairment of patients with schizophrenia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-023-04552-y.
format Online
Article
Text
id pubmed-9872384
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98723842023-01-25 Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia Haddad, Chadia Salameh, Pascale Sacre, Hala Clément, Jean-Pierre Calvet, Benjamin BMC Psychiatry Research BACKGROUND: Patients with psychosis frequently use a variety of psychotropic medicines, many of which have anticholinergic effects that can impair cognition. Therefore, this study aimed to evaluate whether there is an association between medications used for neuropsychological disorders/symptoms and cognition in patients with schizophrenia, focusing on their anticholinergic load and antipsychotic doses. STUDY DESIGN: A cross-sectional study between July 2019 and Mars 2020 at the Psychiatric Hospital of the Cross-Lebanon enrolled 120 inpatients diagnosed with schizophrenia. The total anticholinergic burden was calculated based on the Anticholinergic Drug Scale (ADS), and the chlorpromazine equivalent dose was calculated using the Andreasen method to assess the relative antipsychotic dose. Also, the objective cognition was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS) tool. Study results. A significantly higher BACS total score (r = -0.33, p < 0.001), higher verbal memory (r = -0.26, p = 0.004), higher working memory (r = -0.20, p = 0.03), higher motor speed (r = -0.36, p < 0.001), and higher attention and speed of information processing (r = -0.27, p = 0.003) were significantly associated with lower chlorpromazine equivalent dose. Higher ADS (Standardized Beta (SB) = -.22; p = .028), higher chlorpromazine equivalent dose (SB = -.30; p = .001), and taking mood stabilizer medications (SB = -.24; p = .004) were significantly associated with lower cognition. CONCLUSION: This study confirms that the cognitive functions of chronic patients with schizophrenia may be affected by medications and their anticholinergic burden. More studies are needed to explain the role of cholinergic neurotransmission and general neurochemical mechanisms in the cognitive impairment of patients with schizophrenia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-023-04552-y. BioMed Central 2023-01-24 /pmc/articles/PMC9872384/ /pubmed/36694187 http://dx.doi.org/10.1186/s12888-023-04552-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Haddad, Chadia
Salameh, Pascale
Sacre, Hala
Clément, Jean-Pierre
Calvet, Benjamin
Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
title Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
title_full Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
title_fullStr Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
title_full_unstemmed Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
title_short Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
title_sort effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872384/
https://www.ncbi.nlm.nih.gov/pubmed/36694187
http://dx.doi.org/10.1186/s12888-023-04552-y
work_keys_str_mv AT haddadchadia effectsofantipsychoticandanticholinergicmedicationsoncognitioninchronicpatientswithschizophrenia
AT salamehpascale effectsofantipsychoticandanticholinergicmedicationsoncognitioninchronicpatientswithschizophrenia
AT sacrehala effectsofantipsychoticandanticholinergicmedicationsoncognitioninchronicpatientswithschizophrenia
AT clementjeanpierre effectsofantipsychoticandanticholinergicmedicationsoncognitioninchronicpatientswithschizophrenia
AT calvetbenjamin effectsofantipsychoticandanticholinergicmedicationsoncognitioninchronicpatientswithschizophrenia